FDA clears Novartis’ new treatment for nAMD

Novartis has secured US regulatory approval for Beovu, the company’s latest therapy for neovascular age-related macular degeneration (nAMD), following the drug’s comparable results in head-to-head trials with Eylea. Read more

©2019 All Rights Reserved. Insight is a registered trademark of Prime Creative Media.